Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alex Denner

In a recent filing with the US Securities and Exchange Commission, Alex Denner‘s Sarissa Capital Management has reported entering into an amendment to the nomination agreement with Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). Under the terms of the amendment, the standstill provisions were terminated and Sarissa will not submit a director nomination notice or business proposal under Aegerion’s bylaws for the company’s 2016 meeting of shareholders.

Sarissa owns 2.58 million shares of Aegerion Pharmaceuticals, according to its last 13F filing. Overall, 15 funds from our database reported long positions in the company as of the end of December, down by one over the quarter. The largest position among the investors we track, is held by Matt Sirovich and Jeremy Mindich’s Scopia Capital, which disclosed a $57.6 million stake in its last 13F filing, followed by Kevin Kotler’s Broadfin Capital with a $35.5 million holding. On the other hand, Conan Laughlin’s North Tide Capital unloaded its entire holding in Aegerion that was worth $12.5 million.

You can access the original SEC filing by clicking here.

Alex Denner
Alex Denner
Sarissa Capital Management

Page 1 of 3 – SEC Filing

CUSIP No.  00767E102
Page 1 of  3 Pages
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
Aegerion Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
(CUSIP Number)
Mark DiPaolo
General Counsel
Sarissa Capital Management LP
660 Steamboat Road
Greenwich, CT 06830
With a copy to:
Russell Leaf
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 21, 2016
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be  subject to all other  provisions of the Act  (however, see the Notes).
Follow Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)
Trade (NASDAQ:AEGR) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.